-

Tandem Diabetes Care Appoints Leading Artificial Pancreas Researcher Dr. Jordan Pinsker as Medical Director

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Jordan Pinsker, MD, to Vice President and Medical Director, effective April 26, 2021.

Dr. Pinsker is a leading pediatric endocrinologist and prominent thought leader in artificial pancreas research. He joins Tandem from Sansum Diabetes Research Institute in Santa Barbara, where he has served as the Director of Artificial Pancreas Technology since 2018. In his role at Sansum, he was a lead investigator in numerous clinical trials on automated insulin delivery systems, including Basal-IQ® and Control-IQ™ technology.

“Dr. Pinsker brings extensive knowledge in patient care, diabetes epidemiology, and physician practice efficiency, in addition to sharing our passion for improving the lives of people with diabetes,” said John Sheridan, president and CEO of Tandem Diabetes Care. “We welcome him to Tandem’s management team as we work together to lead in insulin therapy management using our automated insulin delivery technology and flagship pumps.”

Joining us from the Sansum Diabetes Research Institute in Santa Barbara, California, Dr. Pinsker most recently served as director of automated insulin delivery studies. His work included studies sponsored by NIH, JDRF, and Helmsley Charitable Trust and investigator-initiated and industry-funded trials in collaboration with numerous partner sites around the world. His research has focused on testing algorithms used in closed-loop insulin delivery systems, clinical decision support systems, automated exercise detection and management in people with diabetes, improving the quality of continuous glucose monitoring devices, and using all of these technologies to advance the state of closed-loop insulin delivery. Previously, he was Chief of Pediatric Endocrinology at Tripler Army Medical Center in Hawaii. Dr. Pinsker served as a physician in the United States Army in both Active Duty and in the California Army National Guard for more than 20 years. He completed a combined seven-year BS/MD program with Union College and Albany Medical College in New York. Dr. Pinsker is board certified in Clinical Informatics, Pediatric Endocrinology and General Pediatrics.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. The t:slim X2 pump is capable of remote feature updates using a personal computer, and is the only automated insulin dosing device approved for children as young as six years old. Tandem is based in San Diego, California.

Tandem Diabetes Care, Basal-IQ, Control-IQ, and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries.

Contacts

Media: Steve Sabicer, 714-907-6264, ssabicer@thesabicergroup.com
Investors: Susan Morrison, 858-366-6900 x7005, IR@tandemdiabetes.com

Tandem Diabetes Care, Inc.

NASDAQ:TNDM

Release Summary
Tandem Diabetes Care today announced the appointment of Jordan Pinsker, MD, to Vice President and Medical Director, effective April 26, 2021.
Release Versions
$Cashtags

Contacts

Media: Steve Sabicer, 714-907-6264, ssabicer@thesabicergroup.com
Investors: Susan Morrison, 858-366-6900 x7005, IR@tandemdiabetes.com

Social Media Profiles
More News From Tandem Diabetes Care, Inc.

Tandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2025 results after the financial markets close on Wednesday, August 6, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2025 financial and operating results. A live webcast of the call will be available on Tandem Dia...

Tandem Diabetes Care Announces t:slim X2™ Insulin Pump Compatibility with Abbott’s FreeStyle Libre® 3 Plus Sensor in the United States

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company today announced the Tandem t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology now works with Abbott’s FreeStyle Libre® 3 Plus continuous glucose monitoring (CGM) sensor. The Company has initiated an early access program in the United States (U.S.), and intends to scale availability in the second half of 2025. “Diabetes management is...

Tandem Diabetes Care Announces Agreement with Abbott for Integration of Automated Insulin Delivery Systems with Future Glucose-Ketone Sensor

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes. The Abbott sensor, currently under development, will combine glucose and ketone sensing technology that aims to h...
Back to Newsroom